RS64819B1 - Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma - Google Patents

Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma

Info

Publication number
RS64819B1
RS64819B1 RS20231061A RSP20231061A RS64819B1 RS 64819 B1 RS64819 B1 RS 64819B1 RS 20231061 A RS20231061 A RS 20231061A RS P20231061 A RSP20231061 A RS P20231061A RS 64819 B1 RS64819 B1 RS 64819B1
Authority
RS
Serbia
Prior art keywords
compound
schizophrenia
use according
formula
treatment
Prior art date
Application number
RS20231061A
Other languages
English (en)
Serbian (sr)
Inventor
Remy Henri Luthringer
Lorenzo Pellegrini
Argeris Karabelas
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of RS64819B1 publication Critical patent/RS64819B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0003Two-dimensional division
    • H04L5/0005Time-frequency
    • H04L5/0007Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • H04L5/0019Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053Allocation of signalling, i.e. of overhead other than pilot signals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20231061A 2010-07-20 2011-07-20 Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma RS64819B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
EP16181339.9A EP3135286B1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia and symptoms thereof

Publications (1)

Publication Number Publication Date
RS64819B1 true RS64819B1 (sr) 2023-12-29

Family

ID=45497166

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20231061A RS64819B1 (sr) 2010-07-20 2011-07-20 Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma

Country Status (22)

Country Link
US (3) US20180155318A1 (enExample)
EP (4) EP4494704A3 (enExample)
JP (2) JP6053678B2 (enExample)
KR (1) KR101867633B1 (enExample)
CN (1) CN103220910B (enExample)
BR (1) BR112013001303A2 (enExample)
CA (2) CA3117855C (enExample)
DK (2) DK3135286T3 (enExample)
ES (2) ES2656313T3 (enExample)
FI (1) FI3135286T3 (enExample)
HR (1) HRP20231446T1 (enExample)
HU (1) HUE064157T2 (enExample)
LT (1) LT3135286T (enExample)
NO (1) NO2595484T3 (enExample)
PL (2) PL3135286T3 (enExample)
PT (2) PT3135286T (enExample)
RS (1) RS64819B1 (enExample)
RU (1) RU2576611C2 (enExample)
SI (1) SI3135286T1 (enExample)
SM (1) SMT202300413T1 (enExample)
TW (1) TWI583679B (enExample)
WO (1) WO2012012542A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058212T2 (hu) * 2014-12-02 2022-07-28 Minerva Neurosciences Inc 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére
CN113908156A (zh) * 2016-05-25 2022-01-11 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
CA2069318A1 (en) * 1989-10-27 1991-04-28 Engelbert Ciganek (n-phthalimidoalkyl) piperidines
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
AU2006256583B2 (en) * 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
US20180155318A1 (en) 2018-06-07
EP2595484A4 (en) 2014-04-23
US20220274951A1 (en) 2022-09-01
EP3135286B1 (en) 2023-09-06
SI3135286T1 (sl) 2024-02-29
BR112013001303A2 (pt) 2016-05-17
CA3117855C (en) 2023-01-10
JP2017031159A (ja) 2017-02-09
RU2013107382A (ru) 2014-08-27
SMT202300413T1 (it) 2024-01-10
JP6200561B2 (ja) 2017-09-20
CN103220910A (zh) 2013-07-24
CA2806017A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
EP4494704A3 (en) 2025-04-23
TWI583679B (zh) 2017-05-21
EP3135286A1 (en) 2017-03-01
EP2595484A1 (en) 2013-05-29
PL2595484T3 (pl) 2018-03-30
PL3135286T3 (pl) 2024-04-22
PT2595484T (pt) 2018-01-22
LT3135286T (lt) 2023-11-10
PT3135286T (pt) 2023-11-28
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
US20250179044A1 (en) 2025-06-05
HRP20231446T1 (hr) 2024-03-01
RU2576611C2 (ru) 2016-03-10
NO2595484T3 (enExample) 2018-03-17
KR101867633B1 (ko) 2018-06-15
ES2963362T3 (es) 2024-03-26
CA2806017C (en) 2021-06-29
EP3335731A1 (en) 2018-06-20
WO2012012542A1 (en) 2012-01-26
EP4494704A2 (en) 2025-01-22
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
CN103220910B (zh) 2016-05-11
HUE064157T2 (hu) 2024-02-28
DK2595484T3 (en) 2018-01-22
CA3117855A1 (en) 2012-01-26
FI3135286T3 (fi) 2023-11-15
EP3335731B1 (en) 2024-09-04
EP2595484B1 (en) 2017-10-18
DK3135286T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20250179044A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
WO2015191554A1 (en) Compounds and methods of use to treat schizophrenia
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
CA2461248C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
KR20250105660A (ko) 울로타론트를 이용한 신경정신 약물 변경 방법
WO2023219548A1 (en) Selective dopamine increase
HK1062402A1 (zh) 使用脫氧駱駝蓬堿治療由精神治療藥物中毒引致的中樞神經系統症狀
HK1158065A (en) Treatment for neurological and mental disorders
HK1184674B (en) Treatment for neurological and mental disorders
HK1062402B (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops